Back to Search Results
Image Place holder

Bryan McIver, MD, PhD

Deputy Physician-in-Chief

★★★★★
★★★★★
4.9 (177 ratings)
Specialty: Endocrinology
Sub Specialty: Endocrinology, Diabetes & Metabolism
Program: Endocrine Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Adrenal Carcinoma, Neuroendocrine Tumor, Pituitary Macroadenoma, Pituitary Microadenoma, Pituitary Neoplasm, Thyroid Cancer

Dr. McIver contributes to Moffitt Cancer Center almost 20 years of clinical experience in the care of patients with endocrine diseases, specializing in the evaluation of patients with thyroid nodules and thyroid cancer. He has a particular interest in the management of patients with advanced and aggressive forms of cancer and the role of genetic and molecular techniques to improve the accuracy of diagnosis; to tailor appropriate treatment to a patientdisease. Dr. McIver has a long-standing basic research interest in the genetic regulation of growth, invasion and spread of thyroid tumors of all types. His primary research focus is the use of molecular and genetic information to more accurately diagnose thyroid cancer and to predict outcomes in the disease. Dr. McIver received his MB ChB degree from the University of Edinburgh Medical School in Scotland. He completed an Internal Medicine residency at the Royal Infirmary of Edinburgh, followed by a clinical fellowship and clinical investigator fellowship in Endocrinology at the School of Graduate Medical Education at Mayo Clinic in Rochester, MN. Prior to joining Moffitt, he was employed as Professor and Consultant at the Mayo Clinic and Foundation in the Division of Endocrinology & Metabolism. Amongst his most proud accomplishments, Dr. McIver counts his two commitment to education of medical students, residents and fellows; his involvement as a founding member of the World Congress on Thyroid Cancer, an international conference held every four years; and his appointment as a member of the Endowed and Master Clinician Program at the Mayo Clinic, recognizing excellence in patient care.  


Education & Training

Board Certification:

  • Internal Medicine - Endocrinology, Diabetes & Metabolism

Fellowship:

  • Mayo Graduate School of Medicine - Endocrinology, Metabolism and Diabetes
  • Mayo Graduate School of Medicine - Clinical Investigator Fellow in Endocrinology

Residency:

  • Royal Infimary of Edinburgh - Internal Medicine

Medical School:

  • University of Edinburgh Medical School - MB ChB
Video Profile
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Orloff LA, Noel JE, Stack BC, Russell MD, Angelos P, Baek JH, Brumund KT, Chiang FY, Cunnane MB, Davies L, Frasoldati A, Feng AY, Hegedüs L, Iwata AJ, Kandil E, Kuo J, Lombardi C, Lupo M, Maia AL, McIver B, Na DG, Novizio R, Papini E, Patel KN, Rangel L, Russell JO, Shin J, Shindo M, Shonka DC, Karcioglu AS, Sinclair C, Singer M, Spiezia S, Steck JH, Steward D, Tae K, Tolley N, Valcavi R, Tufano RP, Tuttle RM, Volpi E, Wu CW, Abdelhamid Ahmed AH, Randolph GW. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with. Head Neck. 2022 Mar.44(3):633-660. Pubmedid: 34939714.
  • Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2022 Aug.20(8):925-951. Pubmedid: 35948029.
  • Hicks JK, Howard R, Reisman P, Adashek JJ, Fields KK, Gray JE, McIver B, McKee K, O'Leary MF, Perkins RM, Robinson E, Tandon A, Teer JK, Markowitz J, Rollison DE. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precis Oncol. 2021 May.5. Pubmedid: 34095711. Pmcid: PMC8169076.
  • Roberts EC, Nealon SW, Dhillon J, Tourtelot JB, McIver B, Sexton WJ. Bilateral testicular adrenal rest tumors in a patient with nonclassical congenital adrenal hyperplasia. IJU Case Rep. 2021 Jul.4(4):243-246. Pubmedid: 34258539. Pmcid: PMC8255286.
  • Bayona A, Benavent P, Muriel A, Abuchaibe C, Sharpe SC, Tarasova V, McIver B, Valderrabano P. Outcomes of repeat fineneedle aspiration biopsy for AUS/FLUS thyroid nodules. Eur J Endocrinol. 2021 Aug.185(4):497-506. Pubmedid: 34313606.
  • Zafereo M, McIver B, Vargas S, Domínguez Ruiz-Tagle JM, Steward D, Holsinger FC, Kandil E, Williams MD, Cruz F, Loyola S, Solar A, Roa JC, Leon A, Droppelmann N, Arias T, Lobos M, Kong CS, Busaidy N, Grubbs EG, Graham PH, Stewart J, Tang A, Wang J, Orloff LA, Hernríquez-Henríquez M, Lagos M, Wohllk N, Diaz RE, Véliz J, Horvath E, Tala H, Pineda P, Arroyo P, Vasquez F, Osorio M, Schacter D, Franco C, Medina F, Traipe E, Marin L, Miranda G, Bruce E, Bracamonte Nole M, Mena N, Gonzalez H. A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid. 2020 May.30(5):704-712. Pubmedid: 31910118. Pmcid: PMC7232660.
  • Valderrabano P, Wang X, McIver B. Concerns About Methodology in Study of Thyroid Nodule Gene Expression Classifier-Reply. JAMA Otolaryngol Head Neck Surg. 2020 Mar.146(3):313-314. Pubmedid: 31917407.
  • Valderrabano P, Hallanger-Johnson JE, Thapa R, Wang X, McIver B. Comparison of Postmarketing Findings vs the Initial Clinical Validation Findings of a Thyroid Nodule Gene Expression Classifier: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2019 Sep.145(9):783-792. Pubmedid: 31318389. Pmcid: PMC6647006.
  • Lam CA, McGettigan MJ, Thompson ZJ, Khazai L, Chung CH, Centeno BA, McIver B, Valderrabano P. Ultrasound characterization for thyroid nodules with indeterminate cytology: inter-observer agreement and impact of combining pattern-based and scoring-based classifications in risk stratification. Endocrine. 2019 Nov.66(2):278-287. Pubmedid: 31300961. Pmcid: PMC7771547.
  • Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck. 2019 Apr.41(4):843-856. Pubmedid: 30561068.
  • Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, Faquin WC, Sadow P, Baloch Z, Shindo M, Orloff L, Davies L, Randolph GW. AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Head Neck. 2018 Sep.40(9):1881-1888. Pubmedid: 29947030. Pmcid: PMC6175359.
  • Valderrabano P, Khazai L, Thompson ZJ, Otto KJ, Hallanger-Johnson JE, Chung CH, Centeno BA, McIver B. Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2018 Sep.144(9):788-795. Pubmedid: 30027226. Pmcid: PMC6233620.
  • McIver B, Freeman JL, Shah JP, Shaha AR, Haugen BR, Cohen E, Witterick IJ, Randolph GW. Summary of the Third World Congress on Thyroid Cancer. Thyroid. 2018 Nov.28(11):1401-1405. Pubmedid: 30303467.
  • Valderrabano P, Khazai L, Thompson ZJ, Sharpe SC, Tarasova VD, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Thyroid. 2018 Feb.28(2):210-219. Pubmedid: 29160163. Pmcid: PMC7869885.
  • Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Ne. 2018 Dec.16(12):1429-1440. Pubmedid: 30545990.
  • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Chung CH, Centeno BA, McIver B. Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules. Head Neck. 2018 Aug.40(8):1812-1823. Pubmedid: 29624786. Pmcid: PMC7771319.
  • Valderrabano P, McGettigan MJ, Lam C, Khazai L, Thompson ZJ, Chung CH, Centeno BA, McIver B. Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk Stratification. Thyroid. 2018 Aug.28(8):1004-1012. Pubmedid: 29848195. Pmcid: PMC6916126.
  • Araujo Castro M, McIver B, Valderrabano P. A thyrotropin-secreting pituitary adenoma treated with radiosurgery: Long-term outcomes. Endocrinol Diabetes Nutr (Engl Ed). 2018 04.65(4):237-238. Pubmedid: 29426625.
  • Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach. Thyroid. 2017 Oct.27(10):1277-1284. Pubmedid: 28806881. Pmcid: PMC6112164.
  • Valderrabano P, McIver B. Evaluation and Management of Indeterminate Thyroid Nodules: The Revolution of Risk Stratification Beyond Cytological Diagnosis. Cancer Control. 2017 Oct.24(5). Pubmedid: 28975825. Pmcid: PMC5937245.
  • Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, Hallanger-Johnson JE, Otto KJ, Rogers KD, Centeno B, McIver B. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer. 2017 Mar.24(3):127-136. Pubmedid: 28104680. Pmcid: PMC7771306.
  • Agrawal N, Evasovich MR, Kandil E, Noureldine SI, Felger EA, Tufano RP, Kraus DH, Orloff LA, Grogan R, Angelos P, Stack BC, McIver B, Randolph GW. Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement. Head Neck. 2017 Jul.39(7):1269-1279. Pubmedid: 28449244.
  • Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Neben Wittich MA, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017 Dec.102(12):4506-4514. Pubmedid: 29029287.
  • Valderrabano P, Montilla Soler J, Mifsud MJ, Leon ME, Centeno BA, Khazai L, Padhya T, McCaffrey TV, Russell JS, McIver B, Otto KJ. Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for Malignancy. Thyroid. 2016 Sep.26(9):1300-1307. Pubmedid: 27324615.
  • Valderrabano P, Leon ME, Centeno BA, Otto KJ, Khazai L, McCaffrey JC, Russell JS, McIver B. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur J Endocrinol. 2016 May.174(5):621-629. Pubmedid: 26903551.
  • Valderrabano P, Klippenstein DL, Tourtelot JB, Ma Z, Thompson ZJ, Lilienfeld HS, McIver B. New American Thyroid Association Sonographic Patterns for Thyroid Nodules Perform Well in Medullary Thyroid Carcinoma: Institutional Experience, Systematic Review, and Meta-Analysis. Thyroid. 2016 Aug.26(8):1093-1100. Pubmedid: 27267210. Pmcid: PMC7871990.
  • Sondak VK, McIver B, Kanetsky PA. Vitamin D and Melanoma: What Do We Tell Our Patients?. J Clin Oncol. 2016 05.34(15):1713-1714. Pubmedid: 27044934.
  • Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, Tremblay G, Forsythe A, McIver B, Cohen EE. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015 Nov.9:1561-1572. Pubmedid: 26604709. Pmcid: PMC4639528.
  • Lairmore TC, Diesen D, Goldfarb M, Milas M, Ying AK, Sharma J, McIver B, Wong RJ, Randolph G. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: TIMING OF MULTIPLE ENDOCRINE NEOPLASIA THYROIDECTOMY AND EXTENT OF CENTRAL NECK LYMPHADENECTOMY. Endocr Pract. 2015 Jul.21(7):839-847. Pubmedid: 26172129.
  • Gallop K, Kerr C, Simmons S, McIver B, Cohen EE. A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases. Qual Life Res. 2015 Feb.24(2):325-338. Pubmedid: 25106505.
  • Valderrabano P, Zota VE, McIver B, Coppola D, Leon ME. Molecular Assays in Cytopathology for Thyroid Cancer. Cancer Control. 2015 Apr.22(2):152-157. Pubmedid: 26068759.
  • Donegan D, McIver B, Algeciras-Schimnich A. Clinical consequences of a change in anti-thyroglobulin antibody assays during the follow-up of patients with differentiated thyroid cancer. Endocr Pract. 2014 Oct.20(10):1032-1036. Pubmedid: 24793919.
  • McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2014 Nov.99(11):4069-4077. Pubmedid: 24780044.
  • Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris Iii JC, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014 May.99(5):1687-1693. Pubmedid: 24606083. Pmcid: PMC4010705.
  • Czerwonka L, Freeman J, McIver B, Randolph GW, Shah JP, Shaha AR, Sherman SI, Tuttle RM, Witterick IJ. Summary of proceedings of the second World Congress on Thyroid Cancer. Head Neck. 2014 Jul.36(7):917-920. Pubmedid: 24677329.
  • Smallridge RC, Chindris AM, Asmann YW, Casler JD, Serie DJ, Reddi HV, Cradic KW, Rivera M, Grebe SK, Necela B, Eberhardt NL, Carr JM, McIver B, Copland JA, Aubrey Thompson E. RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014 Feb.99(2):E338-E347. Pubmedid: 24297791. Pmcid: PMC3913813.
  • McIver B. Evaluating thyroid nodules in the information age: new technologies, new opportunities, new challenges. Endocr Pract. 2014 Apr.20(4):370-373. Pubmedid: 24641936.
  • Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, Hallanger-Johnson J, McIver B, Eberhardt NL. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther. 2013 May.20(5):267-275. Pubmedid: 23598436.
  • McIver B. Evaluation of the thyroid nodule. Oral Oncol. 2013 Jul.49(7):645-653. Pubmedid: 23706806.
  • McIver B. Postoperative surveillance of thyroid carcinoma. Oral Oncol. 2013 Jul.49(7):684-688. Pubmedid: 23706807.
  • Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013 Apr.23(4):449-455. Pubmedid: 23067375.
  • Call JA, Caudill JS, McIver B, Foote RL. A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience. Rare Tumors. 2013.5(3):e37. Pubmedid: 24179649. Pmcid: PMC3804812.
  • Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther. 2012 Sep.19(9):659-665. Pubmedid: 22790962.
  • Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012 Oct.22(10):996-1001. Pubmedid: 22873825. Pmcid: PMC3464064.
  • Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. J Oncol Pract. 2012 May.8(3 Suppl):e1s-e5s. Pubmedid: 22942830. Pmcid: PMC3348595.
  • Duick DS, Klopper J, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B. The Impact of Benign Gene Expression Classifier Test Results on the Endocrinologist-Patient Decision to Operate on Patients with Thyroid Nodules with Indeterminate FNA Cytopathology. Thyroid. 2012 Jul. Pubmedid: 22783846.
  • Ito Y, McIver B, Besic N, Agarwal A. Prognostic factors for thyroid carcinoma originating from follicular cells. J Thyroid Res. 2012 Aug.2012:920631. Pubmedid: 22254148. Pmcid: PMC3255295.
  • Fatourechi MM, Hay ID, McIver B, Sebo TJ, Fatourechi V. Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976-2008. Thyroid. 2011 Jul.21(7):765-772. Pubmedid: 21568724.
  • Placzkowski KA, Reddi HV, Grebe SK, Eberhardt NL, McIver B. The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. PPAR Res. 2011 Jul.2008:672829. Pubmedid: 18989374. Pmcid: PMC2579323.
  • Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, Grebe SK, Eberhardt NL. The Putative PAX8/PPARγ Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPARγ Activity. Genes Cancer. 2011 Jan.2(1):46-55. Pubmedid: 21779480. Pmcid: PMC3111009.
  • Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011 Jan.21(1):25-30. Pubmedid: 21162687.
  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Bhattacharya A, Lea R, Grebe SK. Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma. Pathology. 2010 Sep.42(6):524-533. Pubmedid: 20854070.
  • Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010 Oct.11(10):962-972. Pubmedid: 20851682. Pmcid: PMC3107731.
  • Reddi HV, Madde P, Marlow LA, Copland JA, McIver B, Grebe SK, Eberhardt NL. Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease Prognosis. Genes Cancer. 2010 May.1(5):480-492. Pubmedid: 20827445. Pmcid: PMC2934914.
  • Eberhardt NL, Grebe SK, McIver B, Reddi HV. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010 May.321(1):50-56. Pubmedid: 19883731. Pmcid: PMC2849860.
  • Algeciras-Schimnich A, Milosevic D, McIver B, Flynn H, Reddi HV, Eberhardt NL, Grebe SK. Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin Chem. 2010 Mar.56(3):391-398. Pubmedid: 20056739. Pmcid: PMC3918957.
  • McIver B, Fatourechi MM, Hay ID, Fatourechi V. Graves' disease after unilateral Riedel's thyroiditis. J Clin Endocrinol Metab. 2010 Jun.95(6):2525-2526. Pubmedid: 20525902.
  • Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S, Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol Metab. 2010 Dec.95(12):5338-5347. Pubmedid: 20810568. Pmcid: PMC2999968.
  • Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov.19(11):1167-1214. Pubmedid: 19860577.
  • Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009 Feb.69(4):1536-1544. Pubmedid: 19208833. Pmcid: PMC2644344.
  • Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab. 2009 Dec.94(12):5001-5009. Pubmedid: 19850689.
  • Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B, Grebe SK, Eberhardt NL. ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Ther. 2008 Nov.15(11):750-757. Pubmedid: 18583996. Pmcid: PMC3180921.
  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol. 2008 Jun.215(2):145-154. Pubmedid: 18393366.
  • Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ, Goellner JR. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008 Dec.144(6):980-987. Pubmedid: 19041007.
  • Reddi HV, McIver B, Grebe SK, Eberhardt NL. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. Endocrinology. 2007 Mar.148(3):932-935. Pubmedid: 16946003.
  • Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006 Feb.16(2):109-142. Pubmedid: 16420177.
  • Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK, Eberhardt NL, McIver B. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab. 2005 Jan.90(1):463-468. Pubmedid: 15483076.
  • McIver B, Grebe SK, Eberhardt NL. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep.4(3):221-234. Pubmedid: 15379724.
  • Gregory Powell J, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL, McIver B. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene. 2004 Apr.23(20):3634-3641. Pubmedid: 15077183.
  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK. Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution. J Clin Endocrinol Metab. 2003 Jul.88(7):3284-3291. Pubmedid: 12843177.
  • Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL. Is there a role for radiation therapy in the management of Hürthle cell carcinoma?. Int J Radiat Oncol Biol Phys. 2003 Jul.56(4):1067-1072. Pubmedid: 12829143.
  • Powell JG, Goellner JR, Nowak LE, McIver B. Rosai-Dorfman disease of the thyroid masquerading as anaplastic carcinoma. Thyroid. 2003 Feb.13(2):217-221. Pubmedid: 12699598.
  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK. Optimising restriction enzyme cleavage of DNA derived from archival histopathological samples: an improved HUMARA assay. Pathology. 2003 Feb.35(1):70-74. Pubmedid: 12701689.
  • Fatourechi V, Klee GG, Grebe SK, Bahn RS, Brennan MD, Hay ID, McIver B, Morris JC. Effects of reducing the upper limit of normal TSH values. Jama. 2003 Dec.290(24):3195-3196. Pubmedid: 14693871.
  • Arnold AM, Anderson GW, McIver B, Eberhardt NL. A novel dynamin III isoform is up-regulated in the central nervous system in hypothyroidism. Int J Dev Neurosci. 2003 Aug.21(5):267-275. Pubmedid: 12850060.
  • Farrand K, Delahunt B, Wang XL, McIver B, Hay ID, Goellner JR, Eberhardt NL, Grebe SK. High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene. J Clin Endocrinol Metab. 2002 Oct.87(10):4715-4721. Pubmedid: 12364463.
  • Velickovic M, Delahunt B, McIver B, Grebe SK. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol. 2002 May.15(5):479-485. Pubmedid: 12011252.
  • Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. Ajr Am J Roentgenol. 2002 Mar.178(3):699-704. Pubmedid: 11856701.
  • Farrand K, Jovanovic L, Delahunt B, McIver B, Hay ID, Eberhardt NL, Grebe SK. Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. J Mol Diagn. 2002 Aug.4(3):150-158. Pubmedid: 12169676. Pmcid: PMC1906979.
  • Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002 Aug.26(8):879-885. Pubmedid: 12016468.
  • McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001 Dec.130(6):1028-1034. Pubmedid: 11742333.
  • McIver B, Grebe SK, Wang L, Hay ID, Yokomizo A, Liu W, Goellner JR, Grant CS, Smith DI, Eberhardt NL. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. Clin Endocrinol. 2000 Jun.52(6):749-757. Pubmedid: 10848880.
  • McIver B, Grebe SKG, Wang L, Hay ID, Yokomizo , Liu W, Goellner JR, Grant CS, Smith DI, Eberhardt NL. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. Clin Endocrinol. 2000 Jun.52(6):749-757. Pubmedid: 28796361.
  • Brink JS, van Heerden JA, McIver B, Salomao DR, Farley DR, Grant CS, Thompson GB, Zimmerman D, Hay ID. Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery. 2000 Dec.128(6):881-886. Pubmedid: 11114619.
  • Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999 May.59(9):2136-2141. Pubmedid: 10232600.
  • Smith JS, Tachibana I, Allen C, Chiappa SA, Lee HK, McIver B, Jenkins RB, Raffel C. Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus. Genomics. 1999 Jul.59(1):97-101. Pubmedid: 10395805.
  • Hay ID, Bergstralh EJ, Grant CS, McIver B, Thompson GB, van Heerden JA, Goellner JR. Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery. 1999 Dec.126(6):1173-1181. Pubmedid: 10598204.
  • Zhang JS, Nelson M, McIver B, Hay ID, Goellner JR, Grant CS, Eberhardt NL, Smith DI. Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors. Oncogene. 1998 Aug.17(6):789-793. Pubmedid: 9715281.
  • Grebe SK, McIver B, Hay ID, Wu PS, Maciel LM, Drabkin HA, Goellner JR, Grant CS, Jenkins RB, Eberhardt NL. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab. 1997 Nov.82(11):3684-3691. Pubmedid: 9360526.
  • McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996 Jan.334(4):220-224. Pubmedid: 8531998.
  • Hart SP, McIver B, Frier BM, Agius RM. Abdominal pain and vomiting in a paint stripper. Postgrad Med J. 1996 Apr.72(846):253-255. Pubmedid: 8733544. Pmcid: PMC2398416.
  • Hepburn DA, Clark CV, Pell AC, McIver B, Frier BM. Changes in the anterior chamber of the eye during acute hypoglycaemia in humans. Clin Sci (Lond). 1993 Jul.85(1):101-104. Pubmedid: 8149685.
  • Wieczorek I, Pell AC, McIver B, MacGregor IR, Ludlam CA, Frier BM. Coagulation and fibrinolytic systems in type I diabetes: effects of venous occlusion and insulin-induced hypoglycaemia. Clin Sci (Lond). 1993 Jan.84(1):79-86. Pubmedid: 8382139.
  • Pell JP, McIver B, Stuart P, Malone DN, Alcock J. Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic. Br J Gen Pract. 1993 Apr.43(369):152-154. Pubmedid: 8323801. Pmcid: PMC1372358.
  • McIver B, Connacher A, Whittle I, Baylis P, Thompson C. Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm. Brit Med J. 1991 Dec.303(6815):1465-1467. Pubmedid: 1773159. Pmcid: PMC1671669.
  • Kimura JE, McIver B. Potassium channels in mouse spinal cord cells. Adv Exp Med Biol. 1987.221:33-43. Pubmedid: 2449051.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

177 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments